Haleon (NYSE:HLN) Shares Gap Down – Here’s Why

Shares of Haleon PLC Sponsored ADR (NYSE:HLN) gapped down prior to trading on Thursday. The stock had previously closed at $10.00, but opened at $8.55. Haleon shares last traded at $8.5550, with a volume of 8,658,524 shares.

Haleon News Roundup

Here are the key news stories impacting Haleon this week:

• Positive Sentiment: Deutsche Bank upgraded Haleon from “sell” to “hold,” removing a bearish recommendation and potentially helping stabilize the stock after its recent decline. Deutsche Bank Haleon recommendations
• Positive Sentiment: Haleon announced a £500 million share buyback, which could support earnings per share and signal that management views the current valuation as attractive. Haleon cuts 2026 forecast and announces buyback
• Neutral Sentiment: Analysts continue to compare Haleon with other consumer-products companies on valuation. The discussion may attract value-focused investors, but it does not provide a major new company-specific catalyst. ASAIY or HLN value stock comparison
• Negative Sentiment: Haleon cut its 2026 organic revenue growth forecast to 2.5% after reporting weaker-than-expected sales. The downgrade raises concerns about slowing demand, pricing pressure and reduced near-term earnings momentum. Haleon cuts 2026 organic revenue forecast
• Negative Sentiment: Chief Executive Brian McNamara warned employees that “difficult choices” may be required following the sales miss, increasing the risk of cost reductions or restructuring. Haleon CEO warns of difficult choices
• Negative Sentiment: Commentary characterized Haleon’s sales performance as a weakness requiring tougher corrective action, reinforcing investor concerns about the company’s growth trajectory. Haleon sales commentary

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a report on Friday, September 25th. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Haleon in a research note on Tuesday, August 11th. Berenberg Bank reiterated a “buy” rating on shares of Haleon in a report on Wednesday, August 5th. Jefferies Financial Group reissued a “buy” rating on shares of Haleon in a research report on Wednesday, September 23rd. Finally, Zacks Research cut shares of Haleon from a “hold” rating to a “strong sell” rating in a report on Thursday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Haleon has a consensus rating of “Moderate Buy” and an average price target of $4.90.

Haleon Trading Up 1.1%

The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.52 and a current ratio of 0.69. The stock has a market capitalization of $38.14 billion, a PE ratio of 22.21, a price-to-earnings-growth ratio of 1.93 and a beta of 0.14. The business’s 50-day moving average is $9.54 and its two-hundred day moving average is $9.77.

Institutional Trading of Haleon

Hedge funds and other institutional investors have recently made changes to their positions in the company. Mondrian Investment Partners LTD purchased a new position in shares of Haleon during the third quarter valued at approximately $158,737,000. Arrowstreet Capital Limited Partnership grew its stake in Haleon by 82.8% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 14,674,518 shares of the company’s stock worth $146,892,000 after acquiring an additional 6,647,329 shares during the period. Bank of America Corp DE grew its stake in Haleon by 17.0% in the 1st quarter. Bank of America Corp DE now owns 10,934,228 shares of the company’s stock worth $109,452,000 after acquiring an additional 1,586,230 shares during the period. Bank Julius Baer & Co. Ltd Zurich grew its stake in Haleon by 4.9% in the 3rd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 4,701,182 shares of the company’s stock worth $42,409,000 after acquiring an additional 219,567 shares during the period. Finally, Royal Bank of Canada raised its holdings in Haleon by 8.5% in the 1st quarter. Royal Bank of Canada now owns 3,063,916 shares of the company’s stock valued at $30,671,000 after acquiring an additional 238,841 shares during the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

About Haleon

Haleon plc (NYSE: HLN) is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.

Haleon’s well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company’s products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.

Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.